[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eupraxia Pharmaceuticals Inc (EPRX)

Eupraxia Pharmaceuticals Inc (EPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 429,081
  • Shares Outstanding, K 60,434
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,580 K
  • EBIT $ -47 M
  • EBITDA $ -47 M
  • 60-Month Beta 1.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 4
  • High Estimate $-0.23
  • Low Estimate $-0.29
  • Prior Year $-0.26
  • Growth Rate Est. (year over year) +3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.26 +13.42%
on 05/19/26
8.13 -12.67%
on 05/01/26
+0.04 (+0.57%)
since 04/22/26
3-Month
6.26 +13.42%
on 05/19/26
8.60 -17.44%
on 02/23/26
-1.40 (-16.47%)
since 02/20/26
52-Week
3.67 +93.46%
on 05/23/25
9.32 -23.82%
on 01/21/26
+3.28 (+85.92%)
since 05/22/25

Most Recent Stories

More News
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

EREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus EREFS...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis 

This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia’s RESOLVE trial.  At 36 weeks, patients in Cohort...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences

VICTORIA, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of the RESOLVE trial. The data is important because it is...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)

Business Summary

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment...

See More

Key Turning Points

3rd Resistance Point 7.86
2nd Resistance Point 7.61
1st Resistance Point 7.35
Last Price 7.10
1st Support Level 6.85
2nd Support Level 6.60
3rd Support Level 6.34

See More

52-Week High 9.32
Fibonacci 61.8% 7.16
Last Price 7.10
Fibonacci 50% 6.49
Fibonacci 38.2% 5.83
52-Week Low 3.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.